Mosquirix (RTS,S)

A Novel Vaccine for the Prevention of Plasmodium falciparum Malaria

Kyle J Wilby BSP ACPR, PharmD; Tim TY Lau PharmD ACPR FCSHP; Samuel E Gilchrist MSc (Pharm), PhD; Mary HH Ensom PharmD FASHP FCCP FCSHP FCAHS

Disclosures

The Annals of Pharmacotherapy. 2012;46(3):384-393. 

In This Article

Dosage and Administration and Storage

Appropriate doses of Mosquirix are currently being confirmed in Phase 2 and 3 trials, with full adult and child doses of the vaccine being 50 and 25 μg, respectively, of lyophilized RTS,S reconstituted in adjuvant.[10,12–14] The vaccine is administered via intramuscular injection (preferably to the deltoid region), over 3 dosing periods, each 1 month apart, which is consistent with administration of other WHO EPI vaccines. The product is stable for 3 years when stored at temperatures between 2 and 8 °C, but must be used within 6 hours of reconstitution.[9]

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....